GyLDEndo – Mimark

Improving Endometriosis Diagnosis from cervical fluids

Endometriosis affects 1 in 10 women of reproductive age worldwide. It is one of the most common gynecological diseases and, at the same time, one of the most underdiagnosed.

In 70% of cases, symptoms start during adolescence, yet women wait between 4 and 11 years to receive a confirmed diagnosis. Current diagnostic pathways rely on symptom interpretation, multiple medical visits, tests with limited sensitivity in early stages, and often invasive procedures such as laparoscopy.

This diagnostic delay has a profound impact on patients’ quality of life and generates a major burden for healthcare systems, with annual costs estimated at nearly €80 billion.

GyLDEndo was created to address this unmet need. It offers an accessible, reliable, and scientifically robust solution that enables earlier detection of endometriosis, helping to transform the diagnostic journey for patients and healthcare providers.

Proof of concept in 200 cervical swabs demonstrated

Designed for patients with symptoms
Minimally invasive cervical cytology
Protein‑based immunoassay
Results within 48 hours
Cost-effective solution to speed up diagnostic pathways

0MW